Parnassus Investments LLC Trims Stock Position in Repligen Co. (NASDAQ:RGEN)

Parnassus Investments LLC trimmed its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 1.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 381,471 shares of the biotechnology company's stock after selling 7,060 shares during the period. Parnassus Investments LLC owned about 0.68% of Repligen worth $56,771,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Swedbank AB purchased a new stake in shares of Repligen during the first quarter worth approximately $5,518,000. Banque Pictet & Cie SA lifted its stake in shares of Repligen by 74.6% in the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company's stock worth $4,351,000 after buying an additional 14,746 shares in the last quarter. Vanguard Group Inc. boosted its position in Repligen by 0.4% during the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company's stock worth $937,994,000 after acquiring an additional 21,719 shares during the last quarter. Diversified Trust Co grew its stake in Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after acquiring an additional 106 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its holdings in shares of Repligen by 240.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock worth $75,866,000 after purchasing an additional 425,061 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Up 4.1 %

Shares of NASDAQ:RGEN traded up $5.08 during trading on Tuesday, hitting $128.49. The company's stock had a trading volume of 963,091 shares, compared to its average volume of 668,961. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The business has a 50 day moving average price of $140.67 and a two-hundred day moving average price of $143.94. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The company has a market capitalization of $7.20 billion, a PE ratio of -347.26, a P/E/G ratio of 3.75 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. During the same period in the previous year, the firm posted $0.23 EPS. Repligen's revenue for the quarter was up 9.7% on a year-over-year basis. As a group, research analysts expect that Repligen Co. will post 1.52 EPS for the current fiscal year.

Insider Activity at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Stephens reissued an "overweight" rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating on the stock. Benchmark reiterated a "hold" rating on shares of Repligen in a research report on Monday, August 5th. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.